基于当前CD4 T淋巴细胞计数的抗逆转录病毒治疗HIV感染者接种mRNA疫苗后针对严重急性呼吸综合征冠状病毒2的体液与细胞免疫应答
该前瞻性免疫原性评估纳入166例接受抗逆转录病毒治疗的HIV感染者,接种BNT162b2或mRNA-1273后按当前CD4 T细胞计数分层。加强针后1个月,CD4<200/mm3组RBD结合IgG可检出率86.7%、中和抗体滴度≥1:10为70.0%,均显著低于CD4>500/mm3组和HIV阴性对照。CD4 200-500/mm3组仅RBD结合抗体应答低于对照,CD4>500/mm3组免疫应答与HIV阴性人群相当。
要点
- HIV感染者接种mRNA疫苗后多数可产生体液和细胞免疫应答。
- CD4 T细胞<200/mm3者免疫应答显著低于CD4>500/mm3者和HIV阴性对照。
- CD4 T细胞200-500/mm3者仅RBD结合抗体应答低于HIV阴性对照。
核心结论
- 大多数HIV感染者可产生针对SARS-CoV-2的体液和细胞免疫应答,但CD4 T细胞<200/mm3者显著低于CD4>500/mm3者和HIV阴性对照。
- CD4 T细胞200-500/mm3者RBD结合抗体应答低于HIV阴性医务人员,而CD4 T细胞>500/mm3者的免疫应答与HIV阴性人群相当。
研究设计与样本
- 前瞻性免疫原性评估,纳入166例接受抗逆转录病毒治疗并参加SARS-CoV-2疫苗接种项目的HIV感染者。
- 接种BNT162b2或mRNA-1273,按当前CD4 T细胞计数分层:CD4恢复不良(PCDR)<200/mm3、中等CD4恢复(ICDR)200-500/mm3、高CD4恢复(HCDR)>500/mm3。
- 检测RBD结合IgG、SARS-CoV-2中和抗体和IFN-γ释放,以HIV阴性医务人员为对照组。
主要发现
- 加强针后1个月,PCDR组可检出RBD结合IgG的比例为86.7%,ICDR组为100%,HCDR组为98.7%。
- 加强针后1个月,中和抗体滴度≥1:10的比例在PCDR组为70.0%,ICDR组为88.2%,HCDR组为93.1%。
- 与HCDR组相比,PCDR组所有免疫应答参数均显著降低。
- 调整混杂因素后,当前CD4 T细胞<200/mm3显著预测抗RBD、中和抗体和IFN-γ应答水平较低。
- 与HIV阴性医务人员相比,PCDR组所有参数免疫原性持续降低,ICDR组仅RBD结合抗体应答降低,HCDR组所有参数免疫应答相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count. METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used. FINDINGS: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters. CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population.
引用
- Antinori A, Cicalini S, Meschi S, et al. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clin Infect Dis. 2022. PMID: 35366316. doi:10.1093/cid/ciac238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。